BR112022005578A2 - Composições e métodos para tratamento de doenças inflamatórias e imunes - Google Patents

Composições e métodos para tratamento de doenças inflamatórias e imunes

Info

Publication number
BR112022005578A2
BR112022005578A2 BR112022005578A BR112022005578A BR112022005578A2 BR 112022005578 A2 BR112022005578 A2 BR 112022005578A2 BR 112022005578 A BR112022005578 A BR 112022005578A BR 112022005578 A BR112022005578 A BR 112022005578A BR 112022005578 A2 BR112022005578 A2 BR 112022005578A2
Authority
BR
Brazil
Prior art keywords
compositions
treatment
methods
inflammatory
immune diseases
Prior art date
Application number
BR112022005578A
Other languages
English (en)
Inventor
N Cook David
Mckenzie Gregory
E Button Julie
Original Assignee
Prolacta Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolacta Bioscience Inc filed Critical Prolacta Bioscience Inc
Publication of BR112022005578A2 publication Critical patent/BR112022005578A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA TRATAMENTO DE DOENÇAS INFLAMATÓRIAS E IMUNES. São fornecidos neste documento composições, métodos, estratégias, kits e artigos de fabricação que são úteis, inter alia, no tratamento ou na prevenção de doenças ou condições, tal como aquelas que podem estar associadas a inflamação, infecção, alergia, disfunção imune ou disbiose do microbioma intestinal. Em alguns aspectos, a invenção fornece uma combinação sinérgica de um prebiótico, por exemplo, uma mistura de oligossacarídeos de leite humano e uma cepa probiótica, tal como uma cepa capaz de internalizar e consumir os prebióticos, por exemplo, B. longum subsp.infantis.
BR112022005578A 2019-09-24 2020-09-24 Composições e métodos para tratamento de doenças inflamatórias e imunes BR112022005578A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962905256P 2019-09-24 2019-09-24
US202063027739P 2020-05-20 2020-05-20
US202063028743P 2020-05-22 2020-05-22
US202063053224P 2020-07-17 2020-07-17
PCT/US2020/052501 WO2021061991A1 (en) 2019-09-24 2020-09-24 Compositions and methods for treatment of inflammatory and immune diseases

Publications (1)

Publication Number Publication Date
BR112022005578A2 true BR112022005578A2 (pt) 2022-09-20

Family

ID=72896070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005578A BR112022005578A2 (pt) 2019-09-24 2020-09-24 Composições e métodos para tratamento de doenças inflamatórias e imunes

Country Status (12)

Country Link
US (1) US20230068960A1 (pt)
EP (1) EP4034143A1 (pt)
JP (1) JP2022548785A (pt)
KR (1) KR20220066904A (pt)
CN (1) CN114364389A (pt)
AU (1) AU2020354581A1 (pt)
BR (1) BR112022005578A2 (pt)
CA (1) CA3151145A1 (pt)
IL (1) IL291140A (pt)
MX (1) MX2022002949A (pt)
TW (1) TW202126317A (pt)
WO (1) WO2021061991A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111235132A (zh) * 2019-12-23 2020-06-05 浙江工业大学 一种β-半乳糖苷酶、基因、工程菌及其应用
CN112458031B (zh) * 2020-12-23 2022-04-29 江南大学 一株源自白酒酿造窖泥的产乳酸型己酸菌及其应用
CA3204530A1 (en) * 2021-01-12 2022-07-21 Gregory Mckenzie Synbiotic treatment regimens
BR112023026650A2 (pt) * 2021-06-18 2024-03-05 Chr Hansen As Composições para aumentar a resiliência a infecções bacterianas.
EP4370141A1 (en) * 2021-07-13 2024-05-22 AB-Biotics, S.A. Probiotic composition for the treatment of increased intestinal permeability
TW202340451A (zh) * 2021-11-22 2023-10-16 香港中文大學 用於治療脫髮的益生菌組合物
US20230190834A1 (en) * 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
KR102616020B1 (ko) * 2021-12-31 2023-12-22 매일유업 주식회사 모유 올리고당 혼합물을 유효성분으로 포함하는 장관면역 개선용, 장 염증 예방 또는 개선용 조성물
CN115029270B (zh) * 2022-06-21 2023-11-28 江南大学 一株能够降低肠道促炎细胞因子的清酒乳杆菌及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5374730A (en) 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20020182243A1 (en) 2001-05-14 2002-12-05 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
CA2623483A1 (en) 2005-09-20 2007-03-29 Prolacta Bioscience, Inc. A method for testing milk
EP2063722B1 (en) 2006-08-30 2017-05-03 Prolacta Bioscience, Inc. Methods of obtaining sterile milk and compositions thereof
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
EP3485742B1 (en) 2006-11-29 2021-09-01 Prolacta Bioscience, Inc. Human milk compositions and methods of making and using same
CN102300575A (zh) 2008-12-02 2011-12-28 普罗莱克塔生物科学公司 人乳渗透物组合物及其制备和使用方法
SG191393A1 (en) * 2010-12-31 2013-08-30 Abbott Lab Neutral human milk oligosaccharides to promote growth of beneficial bacteria
EP2479263B1 (en) 2011-01-20 2013-11-27 Jennewein Biotechnologie GmbH Novel Fucosyltransferases and their applications
EP2760875A4 (en) 2011-09-30 2015-08-26 Glycom As SYNTHESIS OF HMO NUCLEAR STRUCTURES
EP2828275B1 (en) 2012-03-20 2017-03-01 Glycom A/S Synthesis of the trisaccharide 3-o-fucosyllactose and intermediates thereof
WO2013182206A1 (en) 2012-06-08 2013-12-12 Glycom A/S Method for producing oligosaccharides and oligosaccharide glycosides by fermentation
WO2013190531A1 (en) 2012-06-22 2013-12-27 Glycom A/S Glycosylated galactosyl disaccharides, methods for their production and their use in consumable products
WO2013190530A1 (en) 2012-06-22 2013-12-27 Glycom A/S Modified galactooligosaccharides
PL2868206T3 (pl) * 2012-07-05 2017-03-31 Centro Nacional De Tecnología Y Seguridad Alimentaria, Laboratorio Del Ebro Mikrocząsteczki do kapsułkowania probiotyków, ich przygotowywanie i zastosowania
WO2014135167A1 (en) 2013-03-08 2014-09-12 Glycom A/S Purification of oligosaccaharides by reversible derivatization
GB201306689D0 (en) 2013-04-12 2013-05-29 Glycom As Synthesis of sialylated/fucosylated human milk oligosaccharides
GB201306687D0 (en) 2013-04-12 2013-05-29 Glycom As Synthesis of sialylated/fucosylated oligosaccharides
WO2015032413A1 (en) 2013-09-06 2015-03-12 Glycom A/S Fermentative production of oligosaccharides
EP2845905B8 (en) 2013-09-10 2021-07-14 Chr. Hansen HMO GmbH Production of oligosaccharides
EP2857410A1 (en) 2013-10-04 2015-04-08 Jennewein Biotechnologie GmbH Process for purification of 2´-fucosyllactose using simulated moving bed chromatography
DK2896628T3 (en) 2014-01-20 2019-01-14 Jennewein Biotechnologie Gmbh Process for Effective Purification of Neutral Milk Oligosaccharides (HMOs) from Microbial Fermentation
ES2715010T3 (es) 2014-03-31 2019-05-31 Jennewein Biotechnologie Gmbh Fermentación total de oligosacáridos
US10731193B2 (en) 2014-06-27 2020-08-04 Glycom A/S Oligosaccharide production
WO2016183577A1 (en) * 2015-05-14 2016-11-17 Crestovo Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
EP3141610A1 (en) 2015-09-12 2017-03-15 Jennewein Biotechnologie GmbH Production of human milk oligosaccharides in microbial hosts with engineered import / export
WO2017101958A1 (en) 2015-12-18 2017-06-22 Glycom A/S Fermentative production of oligosaccharides
EP3426270A4 (en) * 2016-03-11 2020-04-01 Evolve Biosystems, Inc. TRANSIENT COMMUNAL MICROORGANISM TO IMPROVE THE COLONAL HEALTH
WO2018053535A1 (en) 2016-09-19 2018-03-22 Prolacta Bioscience, Inc. Purified human milk oligosaccharides compositions
ES2856749T3 (es) 2016-10-29 2021-09-28 Chr Hansen Hmo Gmbh Proceso para la producción de oligosacáridos fucosilados
EP3425052A1 (en) 2017-07-07 2019-01-09 Jennewein Biotechnologie GmbH Fucosyltransferases and their use in producing fucosylated oligosaccharides
EP3450443A1 (en) 2017-08-29 2019-03-06 Jennewein Biotechnologie GmbH Process for purifying sialylated oligosaccharides

Also Published As

Publication number Publication date
AU2020354581A1 (en) 2022-03-03
CA3151145A1 (en) 2021-04-01
TW202126317A (zh) 2021-07-16
KR20220066904A (ko) 2022-05-24
EP4034143A1 (en) 2022-08-03
US20230068960A1 (en) 2023-03-02
JP2022548785A (ja) 2022-11-21
IL291140A (en) 2022-05-01
CN114364389A (zh) 2022-04-15
MX2022002949A (es) 2022-04-06
WO2021061991A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
BR112022005578A2 (pt) Composições e métodos para tratamento de doenças inflamatórias e imunes
CO2017012829A2 (es) Composiciones que comprenden cepas bacterianas
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
BR112015030389A2 (pt) uso de i) uma fonte de proteína, ii) um prebiótico e iii) um probiótico para a fabricação de uma composição nutricional para o tratamento ou a prevenção de infecção em um indivíduo alérgico
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
CL2022000057A1 (es) Métodos y productos para el tratamiento de trastornos gastrointestinales
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
BR112018005195A2 (pt) lactobacillus plantarum lc27, composição farmacêutica para a prevenção ou tratamento de uma ou mais doenças, composição alimentícia para a prevenção ou tratamento de uma ou mais doenças, método de prevenção ou tratamento de uma ou mais doenças, e uso de uma composição que compreende lactobacillus plantarum lc27
BR112017019468A2 (pt) composições que metabolizam ou sequestram monômeros de açúcar livres e seus usos
BR112017018656A2 (pt) bactéria modificada para tratar doenças que se beneficiam a partir de inflamação intestinal reduzida e/ou fortalecimento da barreira mucosa intestinal
BR112018015121A2 (pt) cepa bacteriana da espécie faecalibacterium prausnitzii cncm i-4573 para o tratamento e a prevenção da inflamação gastrointestinal
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112017002627A2 (pt) prebióticos para reduzir o risco de obesidade no futuro
BR112022000280A2 (pt) Cepa bacteriana de bifidobacterium bifidum, suas composições e usos relacionados
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
AR102085A1 (es) Composición nutricional para el entorno gastrointestinal para la provisión de un perfil metabólico y microbioma mejorados
BR112017018929A2 (pt) uso de um probiotico e um peptídeo derivado de beta-lactoglobulina, composição, kit de peças, método para induzir tolerância oral, e/ou tratamento, prevenção ou redução do risco de ocorrência de alergia em um indivíduo
BR112017026241A2 (pt) composições farmacêuticas e alimentícias para induzir a saciação e prolongar a saciedade em indivíduos que necessitem das mesmas